PerkinElmer to Market Newborn Screening System
BOSTON, Nov. 14 -- PerkinElmer Inc., the leading provider of solutions to newborn screening laboratories, said it is the first company to receive FDA 510(k) clearance to market a comprehensive screening system to identify whether a newborn may become developmentally impaired or risk premature death. PerkinElmer's NeoGram Phenylalanine Test System, consisting of a reagent kit, application software and tandem mass spectrometer, will be used to identify a disorder known as phenylketonuria (PKU) in newborns.
The reagent kit is designed to run exclusively on tandem mass spectrometry equipment, a new technology for newborn screening, PerkinElmer said.
For more information, visit: lifesciences.perkinelmer.com
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024